Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases

Abstract

In pediatric patients with chronic kidney diseases, irbesartan given once a day for 18 weeks significantly reduces arterial pressure and proteinuria, with an excellent tolerability and side effect profile.